Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RXST
stocks logo

RXST

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
27.79M
-30.9%
-0.335
+123.13%
30.89M
-18.48%
-0.328
+63.78%
33.04M
-1.78%
-0.310
+6.76%
Estimates Revision
The market is revising No Change the revenue expectations for RxSight, Inc. (RXST) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 40.49%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+40.49%
In Past 3 Month
Wall Street analysts forecast RXST stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXST is 9.60 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast RXST stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXST is 9.60 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
4 Hold
2 Sell
Hold
Current: 12.490
sliders
Low
8.00
Averages
9.60
High
12.00
Current: 12.490
sliders
Low
8.00
Averages
9.60
High
12.00
Morgan Stanley
Equal Weight
maintain
$9 -> $10
2025-12-02
New
Reason
Morgan Stanley
Price Target
$9 -> $10
2025-12-02
New
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on RxSight to $10 from $9 and keeps an Equal Weight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.
JPMorgan
Underweight
maintain
$8 -> $9
2025-11-06
Reason
JPMorgan
Price Target
$8 -> $9
2025-11-06
maintain
Underweight
Reason
JPMorgan raised the firm's price target on RxSight to $9 from $8 and keeps an Underweight rating on the shares. The company's Q3 report cleared a low bar but its growth outlook remains uncertain, the analyst tells investors in a research note.
Stifel
Hold
maintain
$8 -> $10
2025-11-06
Reason
Stifel
Price Target
$8 -> $10
2025-11-06
maintain
Hold
Reason
Stifel raised the firm's price target on RxSight to $10 from $8 and keeps a Hold rating on the shares. The quarter was better than feared, with revenue of $30M strongly above the firm's and Wall Street's estimates, the analyst tells investors in a research note. The firm added that it senses the Street's $134M 2026 revenue estimate is in a comfortable place.
UBS
Neutral
downgrade
$16 -> $8
2025-08-08
Reason
UBS
Price Target
$16 -> $8
2025-08-08
downgrade
Neutral
Reason
UBS lowered the firm's price target on RxSight to $8 from $16 and keeps a Neutral rating on the shares following the Q2 earnings report. RxSight's commercial strategy pivot is still under way, and its turnaround depends on improving execution, the analyst tells investors in a research note. The firm lacks conviction in raising assumptions, and needs to see evidence that a turnaround is occurring.
Needham
Buy
downgrade
$22 -> $11
2025-08-08
Reason
Needham
Price Target
$22 -> $11
2025-08-08
downgrade
Buy
Reason
Needham lowered the firm's price target on RxSight to $11 from $22 and keeps a Buy rating on the shares after its Q2 results came in-line with its pre-announcement. RxSight has continued on its commercial pivot, which involves providing more support to its existing accounts in an attempt to drive utilization, though the firm is reducing its price target to reflect a lower multiple, the analyst tells investors in a research note.
Morgan Stanley
Overweight -> Equal Weight
downgrade
$20 -> $9
2025-07-15
Reason
Morgan Stanley
Price Target
$20 -> $9
2025-07-15
downgrade
Overweight -> Equal Weight
Reason
Morgan Stanley downgraded RxSight to Equal Weight from Overweight with a price target of $9, down from $20. Morgan Stanley says it doesn't have visibility on RxSight's near-term growth to remain Overweight following the significant slowdown in LDD placements in Q2 as well as a tougher competitive environment, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Rxsight Inc (RXST.O) is -10.12, compared to its 5-year average forward P/E of -27.54. For a more detailed relative valuation and DCF analysis to assess Rxsight Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-27.54
Current PE
-10.12
Overvalued PE
1.22
Undervalued PE
-56.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-26.98
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.73
Undervalued EV/EBITDA
-56.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
8.17
Current PS
0.00
Overvalued PS
11.75
Undervalued PS
4.59
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

RXST News & Events

Events Timeline

(ET)
2025-11-05
16:29:15
RxSight projects FY25 revenue between $125M and $130M, slightly up from previous estimate of $120M to $130M.
select
2025-11-05
16:28:56
RxSight Announces Q3 Earnings Per Share of 4 Cents, Below Consensus Estimate of 23 Cents
select
2025-08-07 (ET)
2025-08-07
16:34:41
RxSight sees FY25 revenue $120M-$130M, consensus $126.37M
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-22Benzinga
Ross Stores Reports Impressive Q3 Earnings, Alongside Enviri, Azenta, and Other Major Stocks Rising on Friday

  • U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones increasing by approximately 150 points on Friday.

  • Ross Stores Financial Results: Ross Stores Inc. reported better-than-expected third-quarter earnings of $1.58 per share and raised its FY25 GAAP EPS guidance, leading to a 6.3% increase in its stock price.

  • Significant Stock Gains: Enviri Corp saw a notable 29.1% rise in its shares after announcing a major sale, while other companies like Datavault AI Inc and Herbalife Ltd also recorded substantial gains.

  • Analyst Upgrades: WillScot Holdings Corp received an upgrade from Baird analyst Andrew Wittmann, boosting its stock price target from $20 to $22, contributing to a 10.4% increase in its shares.

[object Object]
Preview
6.0
11-06Benzinga
Needham Keeps Buy Rating on RxSight and Increases Price Target to $12

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences to improve their market performance.

  • Market Winning Tools: The platform provides tools and resources designed to help traders succeed and capitalize on market opportunities effectively.

[object Object]
Preview
2.0
11-06NASDAQ.COM
Medtech Stocks Surge in After-Hours Trading: RxSight, Penumbra, and Evolus Take the Lead

  • RxSight's After-Hours Surge: RxSight shares jumped 18.1% after reporting a wider net loss and a 14% revenue decline, but improved its full-year revenue guidance and gross margin outlook.

  • Penumbra's Strong Performance: Penumbra's stock rose 16.4% following a strong Q3 with increased net income and revenue, along with a raised full-year revenue forecast.

  • Evolus Continues Gains: Evolus saw a 13.5% increase in after-hours trading after narrowing its net loss and reporting revenue growth, while reaffirming its full-year revenue guidance.

  • Modest Growth for Other Companies: CVRx and Cytek Biosciences also experienced after-hours gains, with CVRx reporting a slight improvement in losses and revenue growth, while Cytek reaffirmed its future revenue guidance despite a net loss.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Rxsight Inc (RXST) stock price today?

The current price of RXST is 12.49 USD — it has increased 5.31 % in the last trading day.

arrow icon

What is Rxsight Inc (RXST)'s business?

RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.

arrow icon

What is the price predicton of RXST Stock?

Wall Street analysts forecast RXST stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXST is 9.60 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Rxsight Inc (RXST)'s revenue for the last quarter?

Rxsight Inc revenue for the last quarter amounts to 30.34M USD, decreased -14.09 % YoY.

arrow icon

What is Rxsight Inc (RXST)'s earnings per share (EPS) for the last quarter?

Rxsight Inc. EPS for the last quarter amounts to -0.24 USD, increased 50.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Rxsight Inc (RXST)'s fundamentals?

The market is revising No Change the revenue expectations for RxSight, Inc. (RXST) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 40.49%.
arrow icon

How many employees does Rxsight Inc (RXST). have?

Rxsight Inc (RXST) has 498 emplpoyees as of December 05 2025.

arrow icon

What is Rxsight Inc (RXST) market cap?

Today RXST has the market capitalization of 513.55M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free